PERSPECTIVE
The FDA cleared Cepheid’s Xpert Hemorrhagic Fever Panel on October 30, and the company announced the decision on November 3. The multiplex PCR panel uses one sample to detect viral RNA from Ebola, Marburg, Lassa and Crimean-Congo hemorrhagic fever viruses. Cepheid reports a run time of about 61 minutes on GeneXpert Dx systems.
These infections can look similar early on. A single panel can help laboratories narrow the possibilities while clinical and public health teams make isolation and notification decisions. The result still has to move through a workflow that can safely handle specimens, run the assay and relay findings to the people who need them.
The assay reports Ebola virus detection without distinguishing the Ebola viruses it covers. The FDA’s clearance and the earlier WHO Emergency Use Listing are separate regulatory milestones. Real-world availability depends on access to the compatible system and cartridges, as well as safe sample handling.